

# Walker Chandiook & Co LLP

Walker Chandiook & Co LLP  
Plot No. 19A, 2nd Floor  
Sector - 16A,  
Noida - 201 301  
Uttar Pradesh, India  
T +91 120 485 5999  
F +91 120 485 5902

## Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

### To the Board of Directors of Jubilant Pharmova Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Jubilant Pharmova Limited ('the Holding Company'), its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') and its associates (refer Annexure 1 for the list of subsidiaries and associates included in the Statement) for the quarter ended 30 September 2023 and the unaudited consolidated year to date financial results for the period 01 April 2023 to 30 September 2023, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the Listing Regulation, to the extent applicable.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.



Chartered Accountants

Offices in Bengaluru, Chandigarh, Chennai, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandiook & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41 Connaught Circus, Outer Circle, New Delhi, 110001, India

# Walker ChandioK & Co LLP

## Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

5. The Statement includes the Group's share of net profit after tax of ₹ 90 million and ₹ 76 million, and total comprehensive income of ₹ 90 million and ₹ 76 million for the quarter and six months period ended on 30 September 2023 respectively in respect of two associates based on their interim financial information, which have not been reviewed by their auditors, and have been furnished to us by the Holding Company's management. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these associates, are based solely on such unreviewed interim financial information. According to the information and explanations given to us by the management, these interim financial information are not material to the Group.

Our conclusion is not modified in respect of this matter.

6. The review of unaudited consolidated quarterly financial results for the period ended 30 June 2023, included in the Statement was carried out and reported by BSR & Co. LLP who have expressed unmodified conclusion vide their review report dated 19 July 2023, whose review report has been furnished to us by the management and which has been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter.

7. The review of unaudited consolidated quarterly and year-to-date financial results for the period ended 30 September 2022 and audit of consolidated financial results for the year ended 31 March 2023 included in the Statement was carried out and reported by BSR & Co. LLP who have expressed unmodified conclusion vide their review report dated 21 October 2022 and unmodified opinion vide their audit report dated 29 May 2023, respectively, whose reports have been furnished to us and which have been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter.

### For Walker ChandioK & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013

  
**Ashish Gupta**  
Partner

Membership No. 504662

UDIN: 23504662BGWGGT8117



Place: Noida

Date: 27 October 2023

# Walker Chandiook & Co LLP

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

## Annexure 1

List of Subsidiaries and Associates included in the Statement

### A) Name of Subsidiaries

1	Jubilant Pharma Limited
2	Jubilant Draximage (USA) Inc.
3	Jubilant Draximage Inc.
4	Draximage (UK) Limited
5	Jubilant Pharma Holdings Inc.
6	Jubilant Clinsys Inc.
7	Jubilant Cadista Pharmaceuticals Inc.
8	Jubilant HollisterStier LLC
9	Jubilant Pharma NV
10	Jubilant Pharmaceuticals NV
11	PSA Supply NV
12	Jubilant Biosys Limited
13	Jubilant Discovery Services LLC
14	Jubilant Clinsys Limited
15	Jubilant First Trust Healthcare Limited
16	Jubilant Draximage Limited
17	Jubilant Innovation (USA) Inc.
18	Jubilant HollisterStier Inc.
19	Draxis Pharma LLC
20	Drug Discovery and Development Solutions Limited
21	Trialstat Solutions Inc.
22	Jubilant HollisterStier General Partnership
23	Jubilant Generics Limited
24	Jubilant Pharma Australia Pty Limited
25	Jubilant Draximage Radiopharmacies Inc.
26	Jubilant Pharma SA Pty Limited
27	Jubilant Therapeutics India Limited
28	Jubilant Therapeutics Inc.
29	Jubilant Business Services Limited
30	Jubilant Episcribe LLC
31	Jubilant Prodel LLC
32	Jubilant Epipad LLC
33	Jubilant Epicore LLC
34	Jubilant Employee Welfare Trust
35	Jubilant Pharma UK Limited
36	Jubilant Biosys Innovative Research Services Pte. Limited
37	Jubilant Pharma ME FZ-LLC
38	1359773 B.C. Unlimited Liability Company



# Walker Chandiook & Co LLP

**Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

## B) Name of Associates

1 SOFIE Bioscience Inc. (including its following subsidiaries)

- a) GRD US PET Operations Inc.
- b) iTheranostics Inc.
- c) N-Molecular, Inc.
- d) Sofie Network, Inc.
- e) SOFIE Co.

2 SPV Laboratories Private Limited



**Jubilant Pharmova Limited**

Regd. Office: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.)

CIN:L24116UP1978PLC004624

Website: www.jubilantpharmova.com, Email: investors@jubl.com, Tel: +91-5924-267437

**Statement of Consolidated Unaudited Financial Results for the Quarter and Half Year ended 30 September 2023**

*(₹ in million)*

Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30 September	30 June	30 September	30 September	30 September	31 March
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		2023	2023	2022	2023	2022	2023
1	<b>Revenue from operations</b>						
	a) Sales/Income from operations	16,667	15,665	15,847	32,332	30,252	62,193
	b) Other operating income	136	204	148	340	260	624
	<b>Total revenue from operations</b>	<b>16,803</b>	<b>15,869</b>	<b>15,995</b>	<b>32,672</b>	<b>30,512</b>	<b>62,817</b>
2	Other income	99	86	131	185	244	383
3	<b>Total Income (1+2)</b>	<b>16,902</b>	<b>15,955</b>	<b>16,126</b>	<b>32,857</b>	<b>30,756</b>	<b>63,200</b>
4	<b>Expenses</b>						
	a) Cost of materials consumed	4,644	4,281	4,396	8,925	8,137	16,664
	b) Purchases of stock-in-trade	584	571	625	1,155	1,209	2,522
	c) Changes in inventories of finished goods, stock-in-trade and work-in progress	345	349	(190)	694	(645)	(407)
	d) Employee benefits expense	5,318	5,477	5,346	10,795	10,638	21,660
	e) Finance costs	661	619	420	1,280	819	1,882
	f) Depreciation, amortization and impairment expense	966	897	939	1,863	1,885	5,540
	g) Other expenses	3,494	3,495	3,631	6,989	7,062	14,616
	<b>Total expenses</b>	<b>16,012</b>	<b>15,689</b>	<b>15,167</b>	<b>31,701</b>	<b>29,105</b>	<b>62,477</b>
5	<b>Profit before share of profit/(loss) of associates and exceptional Items (3-4)</b>	<b>890</b>	<b>266</b>	<b>959</b>	<b>1,156</b>	<b>1,651</b>	<b>723</b>
6	Share of profit/(loss) of associates	90	(14)	(27)	76	(28)	123
7	<b>Profit before exceptional Items and tax (5+6)</b>	<b>980</b>	<b>252</b>	<b>932</b>	<b>1,232</b>	<b>1,623</b>	<b>846</b>
8	Exceptional items	-	-	568	-	568	568
9	<b>Profit before tax (7-8)</b>	<b>980</b>	<b>252</b>	<b>364</b>	<b>1,232</b>	<b>1,055</b>	<b>278</b>
10	<b>Tax expense</b>						
	- Current tax	351	143	926	494	1,315	1,811
	- Deferred tax charge/(credit)	8	49	(611)	57	(777)	(884)
	<b>Total tax expense</b>	<b>359</b>	<b>192</b>	<b>315</b>	<b>551</b>	<b>538</b>	<b>927</b>
11	<b>Net profit/(loss) for the period (9-10)</b>	<b>621</b>	<b>60</b>	<b>49</b>	<b>681</b>	<b>517</b>	<b>(649)</b>
12	<b>Other comprehensive income</b>						
	i) a) Items that will not be reclassified to profit or loss	(7)	50	1	43	3	(145)
	b) Income tax relating to items that will not be reclassified to profit or loss	2	2	(2)	4	(3)	9
	ii) a) Items that will be reclassified to profit or loss	347	46	667	393	1,824	2,341
	b) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Other comprehensive income for the period</b>	<b>342</b>	<b>98</b>	<b>666</b>	<b>440</b>	<b>1,824</b>	<b>2,205</b>
13	<b>Total comprehensive income for the period (11+12)</b>	<b>963</b>	<b>158</b>	<b>715</b>	<b>1,121</b>	<b>2,341</b>	<b>1,556</b>
	<b>Net profit/(loss) attributable to:</b>						
	Owners of the Company	625	64	54	689	525	(610)
	Non-controlling interest	(4)	(4)	(5)	(8)	(8)	(39)
	<b>Other comprehensive income/(loss) attributable to:</b>						
	Owners of the Company	343	98	668	441	1,827	2,208
	Non-controlling interest	(1)	-	(2)	(1)	(3)	(3)
	<b>Total comprehensive income/(loss) attributable to:</b>						
	Owners of the Company	968	162	722	1,130	2,352	1,598
	Non-controlling interest	(5)	(4)	(7)	(9)	(11)	(42)
14	<b>Earnings per share of ₹ 1 each (not annualized for the quarters)</b>						
	Basic (₹)	3.94	0.40	0.34	4.34	3.30	(3.83)
	Diluted (₹)	3.94	0.40	0.34	4.34	3.30	(3.83)
15	<b>Paid-up equity share capital (face value per share ₹ 1)</b>	<b>158</b>	<b>158</b>	<b>159</b>	<b>158</b>	<b>159</b>	<b>159</b>
16	<b>Reserves excluding revaluation reserves (other equity)</b>						<b>53,834</b>
	<b>See accompanying notes to the Consolidated Unaudited Financial Results</b>						



**Jubilant Pharmova Limited**  
Statement of Consolidated Unaudited Assets and Liabilities as at 30 September 2023

(₹ in million)

Sr. No.	Particulars	As at	As at
		30 September	31 March
		(Unaudited)	(Audited)
		2023	2023
<b>A</b>	<b>ASSETS</b>		
1.	<b>Non-current assets</b>		
	Property, plant and equipment	22,500	22,975
	Capital work-in-progress	10,946	7,733
	Goodwill	24,515	24,286
	Other intangible assets	1,496	1,628
	Intangible assets under development	8,641	7,882
	Right-of-use assets	2,737	2,944
	Investment in associates	2,335	2,236
	<b>Financial assets:</b>		
	Investments	330	328
	Loans	4	4
	Other financial assets	204	184
	Deferred tax assets (net)	2,339	2,275
	Income tax assets (net)	302	478
	Other non-current assets	1,583	990
	<b>Total non-current assets</b>	<b>77,932</b>	<b>73,943</b>
2.	<b>Current assets</b>		
	Inventories	13,280	13,805
	<b>Financial assets:</b>		
	Trade receivables	9,036	9,612
	Cash and cash equivalents	9,737	10,139
	Other bank balances	4	4
	Loans	10	11
	Other financial assets	1,231	1,291
	Income tax assets (net)	235	116
	Other current assets	2,531	2,646
	<b>Total current assets</b>	<b>36,064</b>	<b>37,624</b>
	<b>Total assets</b>	<b>113,996</b>	<b>111,567</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
1.	<b>Equity</b>		
	Equity share capital	158	159
	Other equity	53,943	53,834
	<b>Total equity attributable to owners of the Company</b>	<b>54,101</b>	<b>53,993</b>
2.	<b>Non-controlling interest</b>	(87)	(75)
	<b>Total equity</b>	<b>54,014</b>	<b>53,918</b>
3.	<b>Liabilities</b>		
	<b>Non-current liabilities</b>		
	<b>Financial liabilities:</b>		
	Borrowings	31,696	31,104
	Lease liabilities	1,973	2,133
	Other financial liabilities	246	19
	Provisions	933	922
	Deferred tax liabilities (net)	3,214	3,062
	Other non-current liabilities	4,018	2,685
	<b>Total non-current liabilities</b>	<b>42,080</b>	<b>39,925</b>
	<b>Current liabilities</b>		
	<b>Financial liabilities:</b>		
	Borrowings	2,502	2,997
	Lease liabilities	508	534
	Trade payables		
	Total outstanding dues of micro enterprises and small enterprises	131	176
	Total outstanding dues of creditors other than micro enterprises and small enterprises	9,107	8,037
	Other financial liabilities	3,642	3,355
	Other current liabilities	1,167	1,218
	Provisions	734	783
	Current tax liabilities (net)	111	624
	<b>Total current liabilities</b>	<b>17,902</b>	<b>17,724</b>
	<b>Total liabilities</b>	<b>59,982</b>	<b>57,649</b>
	<b>Total equity and liabilities</b>	<b>113,996</b>	<b>111,567</b>



# Jubilant Pharmova Limited

## Note 1: Statement of Consolidated Unaudited Cash Flows for the Half Year ended 30 September 2023

(₹ in million)

Particulars	Half Year Ended	
	30 September	30 September
	(Unaudited)	(Unaudited)
	2023	2022
<b>A. Cash flow from operating activities</b>		
Profit before tax	1,232	1,055
Adjustments:		
Depreciation, amortisation and impairment expense	1,863	1,885
Gain on disposal of property, plant and equipment (net)	(1)	(7)
Finance costs	1,280	819
Exceptional items	-	568
Share-based payment expense	8	5
Unrealised foreign exchange loss/(gain)	47	(31)
Interest income	(118)	(17)
Loss on investments at fair value through profit or loss	1	23
Share of (gain)/loss of associates	(76)	28
	<b>3,004</b>	<b>3,273</b>
<b>Operating cash flow before working capital changes</b>	<b>4,236</b>	<b>4,328</b>
Decrease in trade receivables	603	246
Decrease in loans, other financial assets and other assets	802	429
Decrease/(increase) in inventories	622	(1,026)
Increase in trade payables	1,030	464
Decrease in other financial liabilities, other liabilities and provisions	(1,038)	(1,063)
<b>Cash generated from operations</b>	<b>6,255</b>	<b>3,378</b>
Income tax paid (net of refund)	(943)	(1,295)
<b>Net cash generated from operating activities</b>	<b>5,312</b>	<b>2,083</b>
<b>B. Cash flow from investing activities</b>		
Purchase of property, plant and equipment, other intangible assets (including capital work-in-progress and intangible assets under development)	(4,979)	(3,421)
Proceeds from sale of property, plant and equipment	51	70
Receipt of asset-related government grant	1,397	641
Purchase of investments	-	(126)
Proceeds from sale of investments	-	9
Movement in other bank balances	1	-
Interest received	117	10
<b>Net cash used in investing activities</b>	<b>(3,413)</b>	<b>(2,817)</b>
<b>C. Cash flow from financing activities</b>		
Acquisition of shares by Jubilant Employees Welfare Trust	(274)	-
Proceeds from long term borrowings	1,137	27,108
Repayments of long term borrowings	(643)	(27,571)
Payment of lease liabilities	(327)	(362)
(Repayments of)/proceeds from short term borrowings (net)	(406)	1,221
Dividend paid	(791)	(97)
Finance costs paid	(1,090)	(1,342)
<b>Net cash used in financing activities</b>	<b>(2,394)</b>	<b>(1,043)</b>
<b>D. Effect of exchange rate changes</b>	<b>93</b>	<b>395</b>
<b>Net decrease in cash and cash equivalents (A+B+C+D)</b>	<b>(402)</b>	<b>(1,382)</b>
Add: cash and cash equivalents at the beginning of the period	10,139	9,838
<b>Cash and cash equivalents at the end of the period</b>	<b>9,737</b>	<b>8,456</b>



**Jubilant Pharmova Limited**

Note 2: Consolidated Unaudited Segment wise Revenue, Results, Assets and Liabilities for the Quarter and Half Year ended 30 September 2023

(₹ in million)

Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30 September	30 June	30 September	30 September	30 September	31 March
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		2023	2023	2022	2023	2022	2023
1	<b>Segment revenue</b>						
	a. Radiopharma	7,408	6,907	6,583	14,315	12,498	25,524
	b. Allergy Immunotherapy	1,803	1,514	1,557	3,317	2,857	6,027
	c. Contract Development and Manufacturing Organisation - Sterile Injectables	3,150	2,955	3,171	6,105	6,290	12,710
	d. Generics	1,723	2,023	1,626	3,746	3,413	7,652
	e. Contract Research, Development and Manufacturing Organisation	2,894	2,964	3,531	5,858	6,746	12,928
	f. Proprietary Novel Drugs	-	-	-	-	38	38
	<b>Total</b>	<b>16,978</b>	<b>16,363</b>	<b>16,468</b>	<b>33,341</b>	<b>31,842</b>	<b>64,879</b>
	Less: Inter segment revenue	254	580	530	834	1,434	2,280
	<b>Total segment revenue</b>	<b>16,724</b>	<b>15,783</b>	<b>15,938</b>	<b>32,507</b>	<b>30,408</b>	<b>62,599</b>
	Add: Unallocable corporate	79	86	57	165	104	218
	<b>Total revenue from operations</b>	<b>16,803</b>	<b>15,869</b>	<b>15,995</b>	<b>32,672</b>	<b>30,512</b>	<b>62,817</b>
2	<b>Segment results (profit+/-/loss-) before tax, exceptional items and interest from each segment)</b>						
	a. Radiopharma	1,170	644	1,110	1,814	1,517	2,428
	b. Allergy Immunotherapy	836	488	496	1,324	913	1,951
	c. Contract Development and Manufacturing Organisation - Sterile Injectables	358	203	523	561	1,653	2,673
	d. Generics	(725)	(398)	(1,038)	(1,123)	(2,012)	(4,757)
	e. Contract Research, Development and Manufacturing Organisation	213	169	521	382	823	1,336
	f. Proprietary Novel Drugs	(84)	(100)	(102)	(184)	(169)	(354)
	<b>Total segment results</b>	<b>1,768</b>	<b>1,006</b>	<b>1,510</b>	<b>2,774</b>	<b>2,725</b>	<b>3,277</b>
	Less: i. Interest (Finance costs)	661	619	420	1,280	819	1,882
	ii. Exceptional items and unallocable expenditure (net of unallocable income)	127	135	726	262	851	1,117
	<b>Profit before tax</b>	<b>980</b>	<b>252</b>	<b>364</b>	<b>1,232</b>	<b>1,055</b>	<b>278</b>
3	<b>Segment assets</b>						
	a. Radiopharma	28,225	27,411	26,344	28,225	26,344	27,182
	b. Allergy Immunotherapy	5,176	4,755	4,088	5,176	4,088	5,069
	c. Contract Development and Manufacturing Organisation - Sterile Injectables	30,757	31,000	26,292	30,757	26,292	28,444
	d. Generics	16,917	17,719	21,130	16,917	21,130	19,049
	e. Contract Research, Development and Manufacturing Organisation	16,492	16,572	15,057	16,492	15,057	15,252
	f. Proprietary Novel Drugs	2,183	2,077	1,733	2,183	1,733	1,985
	g. Unallocable corporate assets	14,246	9,930	12,405	14,246	12,405	14,586
	<b>Total segment assets</b>	<b>113,996</b>	<b>109,464</b>	<b>107,049</b>	<b>113,996</b>	<b>107,049</b>	<b>111,567</b>
4	<b>Segment liabilities</b>						
	a. Radiopharma	7,537	5,761	5,360	7,537	5,360	6,861
	b. Allergy Immunotherapy	724	565	595	724	595	615
	c. Contract Development and Manufacturing Organisation - Sterile Injectables	8,187	6,453	3,630	8,187	3,630	6,277
	d. Generics	2,470	2,460	2,783	2,470	2,783	2,815
	e. Contract Research, Development and Manufacturing Organisation	2,618	2,537	2,924	2,618	2,924	2,678
	f. Proprietary Novel Drugs	133	164	78	133	78	91
	g. Unallocable corporate liabilities	38,313	37,702	36,965	38,313	36,965	38,312
	<b>Total segment liabilities</b>	<b>59,982</b>	<b>55,642</b>	<b>52,335</b>	<b>59,982</b>	<b>52,335</b>	<b>57,649</b>






## Jubilant Pharmova Limited

3. These consolidated unaudited financial results have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
4. In July 2021, the U.S. Food and Drug Administration ("USFDA") placed the Roorkee facility under import alert, which restricts supplies to the USA from the Roorkee facility. The USFDA earlier exempted certain products from the import alert subject to certain conditions. During the quarter ended 30 September 2022, the USFDA limited the exemption to one product subject to certain conditions. Also, subsequent to the USFDA inspection in July 2022, the inspection classification has been concluded as "OAI" (Official Action Indicated) in October 2022. The Group continues to engage with the USFDA and take all necessary steps, including comprehensive assessment and engaging independent consultants, to ensure continuous quality improvements to resolve the import alert at the earliest. Manufacturing and supply of pharmaceutical products continues from Roorkee facility to all other markets including an exempted product to the USA.
5. Previous period figures have been regrouped / reclassified to conform to the current period's classification.
6. The above consolidated unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 27 October 2023. These results have been subjected to limited review by the Statutory Auditors of the Company. The review report of the Statutory Auditors is being filed with BSE Limited and National Stock Exchange of India Limited. For more details on consolidated unaudited results, visit Investors section of our website at [www.jubilantpharmova.com](http://www.jubilantpharmova.com) and Financial Results at Corporates section of [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com).

For Jubilant Pharmova Limited

  
Priyavrat Bhartia  
Managing Director



Place : Noida

Date : 27 October 2023